|
1
|
Cunningham D, Atkin W, Lenz HJ, Lynch HT,
Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet.
375:1030–1047. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kerr D: Clinical development of gene
therapy for colorectal cancer. Nat Rev Cancer. 3:615–622. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dalerba P, Dylla SJ, Park IK, Liu R, Wang
X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, et al:
Phenotypic characterization of human colorectal cancer stem cells.
Proc Natl Acad Sci USA. 104:10158–10163. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Puglisi MA, Tesori V, Lattanzi W,
Gasbarrini GB and Gasbarrini A: Colon cancer stem cells:
Controversies and perspectives. World J Gastroenterol.
19:2997–3006. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Horst D, Scheel SK, Liebmann S, Neumann J,
Maatz S, Kirchner T and Jung A: The cancer stem cell marker CD133
has high prognostic impact but unknown functional relevance for the
metastasis of human colon cancer. J Pathol. 219:427–434. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hongo K, Kazama S, Sunami E, Tsuno NH,
Takahashi K, Nagawa H and Kitayama J: Immunohistochemical detection
of CD133 is associated with tumor regression grade after
chemoradiotherapy in rectal cancer. Med oncol. 29:2849–2857. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ying X, Wu J, Meng X, Zuo Y, Xia Q, Chen
J, Feng Y, Liu R, Li L and Huang W: AC133 expression associated
with poor prognosis in stage II colorectal cancer. Med Oncol.
30:3562013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kai K, Nagano O, Sugihara E, Arima Y,
Sampetrean O, Ishimoto T, Nakanishi M, Ueno NT, Iwase H and Saya H:
Maintenance of HCT116 colon cancer cell line conforms to a
stochastic model but not a cancer stem cell model. Cancer Sci.
100:2275–2282. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li XL, Zhou J, Chen ZR and Chng WJ: P53
mutations in colorectal cancer-molecular pathogenesis and
pharmacological reactivation. World J Gastroenterol. 21:84–93.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Naccarati A, Polakova V, Pardini B,
Vodickova L, Hemminki K, Kumar R and Vodicka P: Mutations and
polymorphisms in TP53 gene-an overview on the role in colorectal
cancer. Mutagenesis. 27:211–218. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hall EH, Schoenbach KH and Beebe SJ:
Nanosecond pulsed electric fields induce apoptosis in p53-wildtype
and p53-null HCT116 colon carcinoma cells. Apoptosis. 12:1721–1731.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang B, Xiao Z and Ren EC: Redefining the
p53 response element. Proc Natl Acad Sci USA. 106:14373–14378.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schuster-Bockler B, Schultz J and Rahmann
S: HMM Logos for visualization of protein families. BMC
Bioinformatics. 5:72004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Marinescu VD, Kohane IS and Riva A:
MAPPER: A search engine for the computational identification of
putative transcription factor binding sites in multiple genomes.
BMC Bioinformatics. 6:792005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ricci-Vitiani L, Lombardi DG, Pilozzi E,
Biffoni M, Todaro M, Peschle C and De Maria R: Identification and
expansion of human colon-cancer-initiating cells. Nature.
445:111–115. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
O'Brien CA, Pollett A, Gallinger S and
Dick JE: A human colon cancer cell capable of initiating tumour
growth in immunodeficient mice. Nature. 445:106–110. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q,
Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem
cells promote radioresistance by preferential activation of the DNA
damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu Y and Wu PY: CD133 as a marker for
cancer stem cells: Progresses and concerns. Stem Cells Dev.
18:1127–1134. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen KL, Pan F, Jiang H, Chen JF, Pei L,
Xie FW and Liang HJ: Highly enriched CD133(+)CD44(+) stem-like
cells with CD133(+)CD44 (high) metastatic subset in HCT116 colon
cancer cells. Clin Exp Metastasis. 28:751–763. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang ZL, Zheng Q, Yan J, Pan Y and Wang
ZG: Upregulated CD133 expression in tumorigenesis of colon cancer
cells. World J Gastroenterol. 17:932–937. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chantret I, Barbat A, Dussaulx E, Brattain
MG and Zweibaum A: Epithelial polarity, villin expression and
enterocytic differentiation of cultured human colon carcinoma
cells: A survey of twenty cell lines. Cancer Res. 48:1936–1942.
1988.PubMed/NCBI
|
|
23
|
Konishi H, Asano N, Imatani A, Kimura O,
Kondo Y, Jin X, Kanno T, Hatta W, Ara N, Asanuma K, et al: Notch1
directly induced CD133 expression in human diffuse type gastric
cancers. Oncotarget. 30:56598–56607. 2016.
|
|
24
|
Matsumoto K, Arao T, Tanaka K, Kaneda H,
Kudo K, Fujita Y, Tamura D, Aomatsu K, Tamura T, Yamada Y, et al:
mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133
expression in cancer cells. Cancer Res. 69:7160–7164. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mathieu J, Zhang Z, Zhou W, Wang AJ,
Heddleston JM, Pinna CM, Hubaud A, Stadler B, Choi M, Bar M, et al:
HIF induces human embryonic stem cell markers in cancer cells.
Cancer Res. 71:4640–4652. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Won C, Kim BH, Yi EH, Choi KJ, Kim EK,
Jeong JM, Lee JH, Jang JJ, Yoon JH, Jeong WI, et al: Signal
transducer and activator of transcription 3-mediated CD133
up-regulation contributes to promotion of hepatocellular carcinoma.
Hepatology. 62:1160–1173. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mak AB, Nixon AM and Moffat J: The mixed
lineage leukemia (MLL) fusion-associated gene AF4 promotes CD133
transcription. Cancer Res. 72:1929–1934. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Iida H, Suzuki M, Goitsuka R and Ueno H:
Hypoxia induces CD133 expression in human lung cancer cells by
up-regulation of OCT3/4 and SOX2. Int J Oncol. 40:71–79.
2012.PubMed/NCBI
|
|
29
|
Zhang L, Li H, Ge C, Li M, Zhao FY, Hou
HL, Zhu MX, Tian H, Zhang LX, Chen TY, et al: Inhibitory effects of
transcription factor Ikaros on the expression of liver cancer stem
cell marker CD133 in hepatocellular carcinoma. Oncotarget.
5:10621–10635. 2014.PubMed/NCBI
|
|
30
|
Ohnishi S, Maehara O, Nakagawa K, Kameya
A, Otaki K, Fujita H, Higashi R, Takagi K, Asaka M, Sakamoto N, et
al: hypoxia-inducible factors activate CD133 promoter through ETS
family transcription factors. PLoS One. 8:e662552013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Min KJ, So KA, Ouh YT, Hong JH and Lee JK:
The effects of DNA methylation and epigenetic factors on the
expression of CD133 in ovarian cancers. J Ovarian Res. 5:282012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vogelstein B, Lane D and Levine AJ:
Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Puca F, Colamaio M, Federico A, Gemei M,
Tosti N, Bastos AU, Del Vecchio L, Pece S, Battista S and Fusco A:
HMGA1 silencing restores normal stem cell characteristics in colon
cancer stem cells by increasing p53 levels. Oncotarget.
5:3234–3245. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zeilstra J, Joosten SP, Vermeulen L,
Koster J, Medema JP, Versteeg R, Spaargaren M and Pals ST: CD44
expression in intestinal epithelium and colorectal cancer is
independent of p53 status. PLoS One. 8:e728492013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Park EK, Lee JC, Park JW, Bang SY, Yi SA,
Kim BK, Park JH, Kwon SH, You JS, Nam SW, et al: Transcriptional
repression of cancer stem cell marker CD133 by tumor suppressor
p53. Cell Death Dis. 6:e19642015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shmelkov SV, Butler JM, Hooper AT, Hormigo
A, Kushner J, Milde T, St Clair R, Baljevic M, White I, Jin DK, et
al: CD133 expression is not restricted to stem cells and both
CD133+ and CD133− metastatic colon cancer
cells initiate tumors. J Clin Invest. 118:2111–2120.
2008.PubMed/NCBI
|
|
37
|
Kawamoto H, Yuasa T, Kubota Y, Seita M,
Sasamoto H, Shahid JM, Hayashi T, Nakahara H, Hassan R, Iwamuro M,
et al: Characteristics of CD133(+) human colon cancer SW620 cells.
Cell Transplant. 19:857–864. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rassouli FB, Matin MM and Saeinasab M:
Cancer stem cells in human digestive tract malignancies. Tumour
Biol. 37:7–21. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Smeenk L, van Heeringen SJ, Koeppel M, van
Driel MA, Bartels SJ, Akkers RC, Denissov S, Stunnenberg HG and
Lohrum M: Characterization of genome-wide p53-binding sites upon
stress response. Nucleic Acids Res. 36:3639–3654. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hoh J, Jin S, Parrado T, Edington J,
Levine AJ and Ott J: The p53MH algorithm and its application in
detecting p53-responsive genes. Proc Natl Acad Sci USA.
99:8467–8472. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gowrisankar S and Jegga AG: Regression
based predictor for p53 transactivation. BMC Bioinformatics.
10:2152009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ma B, Pan Y, Zheng J, Levine AJ and
Nussinov R: Sequence analysis of p53 response-elements suggests
multiple binding modes of the p53 tetramer to DNA targets. Nucleic
Acids Res. 35:2986–3001. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Veprintsev DB and Fersht AR: Algorithm for
prediction of tumour suppressor p53 affinity for binding sites in
DNA. Nucleic Acids Res. 36:1589–1598. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tebaldi T, Zaccara S, Alessandrini F,
Bisio A, Ciribilli Y and Inga A: Whole-genome cartography of p53
response elements ranked on transactivation potential. BMC
Genomics. 16:4642015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Botcheva K and McCorkle SR: Cell context
dependent p53 genome-wide binding patterns and enrichment at
repeats. PLoS One. 9:e1134922014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Williams K, Christensen J, Rappsilber J,
Nielsen AL, Johansen JV and Helin K: The histone lysine demethylase
JMJD3/KDM6B is recruited to p53 bound promoters and enhancer
elements in a p53 dependent manner. PLoS One. 9:e965452014.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhao Q, Zhou H, Liu Q, Cao Y, Wang G, Hu
A, Ruan L, Wang S, Bo Q, Chen W, et al: Prognostic value of the
expression of cancer stem cell-related markers CD133 and CD44 in
hepatocellular carcinoma: From patients to patient-derived tumor
xenograft models. Oncotarget. 7:47431–47443. 2016.PubMed/NCBI
|
|
48
|
Thanan R, Pairojkul C, Pinlaor S,
Khuntikeo N, Wongkham C, Sripa B, Ma N, Vaeteewoottacharn K,
Furukawa A, Kobayashi H, et al: Inflammation-related DNA damage and
expression of CD133 and Oct3/4 in cholangiocarcinoma patients with
poor prognosis. Free Radic Biol Med. 65:1464–1472. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Le H, Zeng F, Xu L, Liu X and Huang Y: The
role of CD133 expression in the carcinogenesis and prognosis of
patients with lung cancer. Mol Med Rep. 8:1511–1518. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhuang HW, Mo TT, Hou WJ, Xiong GX, Zhu
XL, Fu QL and Wen WP: Biological characteristics of CD133(+) cells
in nasopharyngeal carcinoma. Oncol Rep. 30:57–63. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wen L, Chen XZ, Yang K, Chen ZX, Zhang B,
Chen JP, Zhou ZG, Mo XM and Hu JK: Prognostic value of cancer stem
cell marker CD133 expression in gastric cancer: A systematic
review. PLoS One. 8:e591542013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kim K, Ro JY, Kim S and Cho YM: Expression
of stem-cell markers OCT-4 and CD133: Important prognostic factors
in papillary renal cell carcinoma. Human Pathol. 43:2109–2116.
2012. View Article : Google Scholar
|
